Bispecific Checkpoint Inhibitor Improves Survival in Advanced Gastric/GEJ Cancer
SAN DIEGO -- A bispecific immune checkpoint inhibitor significantly improved survival in advanced gastric/gastroesophageal junction (GEJ) cancer, irrespective of PD-L1 ...
Read more